Emergex today announced it has successfully completed the first step in the development of a candidate vaccine for the Gram-negative intracellular coccobacillus, Francisella tularensis.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2019-12-12 10:28:432019-12-12 10:29:23Emergex Completes First Step in the Development of a Vaccine Candidate Against Intracellular Bacterium and Bioterrorist Agent Francisella Tularensis
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2019-12-10 09:43:492019-12-12 10:31:22Emergex Successfully Completes Preclinical Testing of its Lead ‘Set-Point’ Vaccine Candidate for Dengue Fever and Other Flaviviruses
Emergex today announced that it has signed an R&D agreement with the Institute of Molecular and Cell Biology (IMCB) in Singapore to develop a fully synthetic vaccine against human viruses that cause Hand, Foot and Mouth Disease (HFMD). Emergex and IMCB will collaborate closely to develop the new vaccine, combining their personnel, specialist knowledge and expertise.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2019-06-27 09:35:392019-12-10 09:42:15Emergex Signs an R&D Agreement with IMCB to Develop a Vaccine for the Emerging Threat of Hand, Foot & Mouth Disease
Emergex today announces the appointment of Athanasios Papadopoulos, MD, as Chief Medical Officer (CMO), effective 1st March 2019. Dr. Papadopoulos will report directly to Emergex’s CEO Professor Thomas Rademacher.
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a novel approach to the development of vaccines for infectious diseases, today announces that it has successfully secured a state-of-the-art-research and development (R&D) facility at Milton Park, Oxfordshire.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2019-02-18 09:34:272019-02-27 10:18:33Emergex Secures State-of-the-art R&D Facility and Hires a Chief Scientific Officer to Drive Development of its Vaccines
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the successful completion of preclinical toxicology testing on the gold nanoparticle carrier system that forms the fundamental basis for Emergex’s entire infectious disease vaccine platform.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2018-10-24 08:59:532019-02-27 10:18:52Emergex Demonstrates Excellent Safety Profile for Gold Nanoparticle Used in its Vaccine Platform
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces that it has signed a Memorandum of Understanding (MoU) with Brazil-based Oswaldo Cruz Foundation ‘Fiocruz’ for the development of viral vaccines. The MoU initially covers the development of a vaccine that universally targets diseases within the flavivirus family such as Dengue Fever, Zika and Yellow Fever but could be expanded to include the development of vaccines to target other viral families that are endemic to the region.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2018-09-20 09:00:472019-02-27 10:19:11Emergex Enters into MoU with Brazil’s Fiocruz to Develop Novel Vaccines Against Viral Diseases
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has appointed The Conafay Group, US Federal Government experts, to advise on the US healthcare landscape and policy and to provide introductions to help establish new business contacts.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2018-07-13 09:37:592019-02-27 10:19:38Emergex Appoints US Federal Government Experts The Conafay Group
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to enable synthetic vaccine development in the field of infectious diseases, today announces that it has filed a patent in the USA for its novel pandemic flu vaccine.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2018-05-24 08:54:282019-02-27 10:19:49Emergex Files a Patent in the USA for its novel Pandemic Flu Vaccine
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2018-05-14 09:11:082019-02-27 10:20:01Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu Vaccine
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Sir David King has joined Emergex’s Board as a Non-Executive Director.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2018-03-29 09:00:342019-02-27 10:20:18Sir David King Joins Emergex’s Board of Directors
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has built its Finance team and strengthening its operational capabilities.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2018-03-28 08:59:382019-02-27 10:21:05Emergex Builds its Finance Team with Two New Recruits
Emergex Vaccines Holding Limited (“Emergex”), a private biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today provides an update on its vaccine development pipeline and business.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2018-03-26 09:15:352019-02-27 10:21:20Emergex Progresses its Synthetic Vaccine Development Pipeline
Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that they have been awarded a £499,825 SBRI contract with the Department of Health/Technology Strategy Board, facilitated by Innovate UK, the UK’s Innovation Agency. The ‘Vaccines for Global Development – Preclinical’ grant proceeds will be used to advance the Zika and multivalent filovirus (Ebola and Marburg) vaccine programmes.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2017-04-05 13:13:212019-02-27 10:21:31Emergex Vaccines awarded SBRI contract by Innovate UK
Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announces that they have been approved as a member of the Social Stock Exchange, society’s market for impact investing. This follows the ratification of Emergex’s impact report by the Social Stock Exchange’s independent Admissions Panel.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2017-02-20 13:14:242019-02-27 10:21:41Emergex Vaccines approved as member of the Social Stock Exchange
Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that it has paid an upfront technology access fee and option payment of £450,000 to Midatech Pharma (AIM: MTPH, NASDAQ: MTP), under the terms of the contract. This follows the licence granted to Emergex from Midatech Pharma, which was announced in January this year.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2016-11-22 13:02:272019-02-27 10:21:52Emergex Vaccines provides an update on Agreement with Midatech Pharma
Emergex Completes First Step in the Development of a Vaccine Candidate Against Intracellular Bacterium and Bioterrorist Agent Francisella Tularensis
/in News /by gatekeeperEmergex today announced it has successfully completed the first step in the development of a candidate vaccine for the Gram-negative intracellular coccobacillus, Francisella tularensis.
Emergex Successfully Completes Preclinical Testing of its Lead ‘Set-Point’ Vaccine Candidate for Dengue Fever and Other Flaviviruses
/in News /by gatekeeperEmergex today announced the successful completion of preclinical testing of its lead vaccine candidate for Dengue Fever.
Emergex Signs an R&D Agreement with IMCB to Develop a Vaccine for the Emerging Threat of Hand, Foot & Mouth Disease
/in News /by gatekeeperEmergex today announced that it has signed an R&D agreement with the Institute of Molecular and Cell Biology (IMCB) in Singapore to develop a fully synthetic vaccine against human viruses that cause Hand, Foot and Mouth Disease (HFMD). Emergex and IMCB will collaborate closely to develop the new vaccine, combining their personnel, specialist knowledge and expertise.
Dr. Athanasios Papadopoulos joins Emergex as Chief Medical Officer
/in News /by gatekeeperEmergex today announces the appointment of Athanasios Papadopoulos, MD, as Chief Medical Officer (CMO), effective 1st March 2019. Dr. Papadopoulos will report directly to Emergex’s CEO Professor Thomas Rademacher.
Emergex Secures State-of-the-art R&D Facility and Hires a Chief Scientific Officer to Drive Development of its Vaccines
/in News /by gatekeeperEmergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a novel approach to the development of vaccines for infectious diseases, today announces that it has successfully secured a state-of-the-art-research and development (R&D) facility at Milton Park, Oxfordshire.
Emergex Demonstrates Excellent Safety Profile for Gold Nanoparticle Used in its Vaccine Platform
/in News /by gatekeeperEmergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the successful completion of preclinical toxicology testing on the gold nanoparticle carrier system that forms the fundamental basis for Emergex’s entire infectious disease vaccine platform.
Emergex Enters into MoU with Brazil’s Fiocruz to Develop Novel Vaccines Against Viral Diseases
/in News /by gatekeeperEmergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces that it has signed a Memorandum of Understanding (MoU) with Brazil-based Oswaldo Cruz Foundation ‘Fiocruz’ for the development of viral vaccines. The MoU initially covers the development of a vaccine that universally targets diseases within the flavivirus family such as Dengue Fever, Zika and Yellow Fever but could be expanded to include the development of vaccines to target other viral families that are endemic to the region.
Emergex Appoints US Federal Government Experts The Conafay Group
/in News /by gatekeeperEmergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has appointed The Conafay Group, US Federal Government experts, to advise on the US healthcare landscape and policy and to provide introductions to help establish new business contacts.
Emergex Files a Patent in the USA for its novel Pandemic Flu Vaccine
/in News /by gatekeeperEmergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to enable synthetic vaccine development in the field of infectious diseases, today announces that it has filed a patent in the USA for its novel pandemic flu vaccine.
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu Vaccine
/in News /by gatekeeperEmergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.
Sir David King Joins Emergex’s Board of Directors
/in News /by gatekeeperEmergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Sir David King has joined Emergex’s Board as a Non-Executive Director.
Emergex Builds its Finance Team with Two New Recruits
/in News /by gatekeeperEmergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has built its Finance team and strengthening its operational capabilities.
Emergex Progresses its Synthetic Vaccine Development Pipeline
/in News /by gatekeeperEmergex Vaccines Holding Limited (“Emergex”), a private biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today provides an update on its vaccine development pipeline and business.
Emergex Vaccines awarded SBRI contract by Innovate UK
/in News /by gatekeeperEmergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that they have been awarded a £499,825 SBRI contract with the Department of Health/Technology Strategy Board, facilitated by Innovate UK, the UK’s Innovation Agency. The ‘Vaccines for Global Development – Preclinical’ grant proceeds will be used to advance the Zika and multivalent filovirus (Ebola and Marburg) vaccine programmes.
Emergex Vaccines approved as member of the Social Stock Exchange
/in News /by gatekeeperEmergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announces that they have been approved as a member of the Social Stock Exchange, society’s market for impact investing. This follows the ratification of Emergex’s impact report by the Social Stock Exchange’s independent Admissions Panel.
Emergex Vaccines provides an update on Agreement with Midatech Pharma
/in News /by gatekeeperEmergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that it has paid an upfront technology access fee and option payment of £450,000 to Midatech Pharma (AIM: MTPH, NASDAQ: MTP), under the terms of the contract. This follows the licence granted to Emergex from Midatech Pharma, which was announced in January this year.